What is the address of DIFARMEX?

The registered office of DIFARMEX is located at Koosterstraat 51, 3570 Alken.

Is DIFARMEX still active?

Yes. According to the CBE (29 October 2026) DIFARMEX is active, legal situation “Normale toestand”, started on 5 August 1994.

Is DIFARMEX registered on Peppol?

No, DIFARMEX is currently not registered on the Peppol network.

What is the enterprise number of DIFARMEX?

The enterprise number of DIFARMEX is BE0453209833.

When was DIFARMEX founded?

DIFARMEX was founded on 5 August 1994.

Who are the directors of DIFARMEX?

According to the 2025 annual accounts, the directors of DIFARMEX are: Stephan Tans, Maria Adams.

Is DIFARMEX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 August 1994; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did DIFARMEX make in 2025?

DIFARMEX recorded a loss after taxes of € 4,091 in financial year 2025.

What is the revenue of DIFARMEX?

As a small company, DIFARMEX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 3,879.

DIFARMEX (Public Limited) - Alken - BE0453209833

Dossier DIFARMEX, printed on 29 October 2026 from databakkes.be/en/0453209833/difarmex. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

DIFARMEX from Alken, company number BE0453209833, closed financial year 2025 with a result of € -4,091 after tax. For that financial year DIFARMEX recorded a gross margin of € 3,879 and equity of € 200,895. Compared with financial year 2024, the result moved from € 8,660 to € -4,091. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.

What it is worth Healthy

€ 200,895

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -4,091

▼ still € 8,660 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 87

▲ 162% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -72,414.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 16,544 Gross margin 2022: € 16,544 First fiscal year in the series	€ 16,625 Gross margin 2023: € 16,625 Unchanged (€ 16,544) Favourable step	€ 16,595 Gross margin 2024: € 16,595 Unchanged (€ 16,625) Unfavourable step	€ 3,879 Gross margin 2025: € 3,879 ▼ 77% vs 2024 (€ 16,595) Unfavourable step	▼ 77%
Profit after taxes	€ 5,975 Profit after taxes 2022: € 5,975 First fiscal year in the series	€ 7,220 Profit after taxes 2023: € 7,220 ▲ 21% vs 2022 (€ 5,975) Favourable step	€ 8,660 Profit after taxes 2024: € 8,660 ▲ 20% vs 2023 (€ 7,220) Favourable step	€ -4,091 Profit after taxes 2025: € -4,091 ▼ € 12,751 vs 2024 (€ 8,660) Unfavourable step	▼ € 12,751
Equity	€ 189,107 Equity 2022: € 189,107 First fiscal year in the series	€ 196,327 Equity 2023: € 196,327 ▲ 4% vs 2022 (€ 189,107) Favourable step	€ 204,986 Equity 2024: € 204,986 ▲ 4% vs 2023 (€ 196,327) Favourable step	€ 200,895 Equity 2025: € 200,895 ▼ 2% vs 2024 (€ 204,986) Unfavourable step	▼ 2%
Total debts	€ 128,314 Total debts 2022: € 128,314 First fiscal year in the series	€ 107,684 Total debts 2023: € 107,684 ▼ 16% vs 2022 (€ 128,314) Favourable step	€ 94,204 Total debts 2024: € 94,204 ▼ 13% vs 2023 (€ 107,684) Favourable step	€ 89,186 Total debts 2025: € 89,186 ▼ 5% vs 2024 (€ 94,204) Favourable step	▼ 5%
Cash	€ 4,556 Cash 2022: € 4,556 First fiscal year in the series	€ 305 Cash 2023: € 305 ▼ 93% vs 2022 (€ 4,556) Unfavourable step	€ 33 Cash 2024: € 33 ▼ 89% vs 2023 (€ 305) Unfavourable step	€ 87 Cash 2025: € 87 ▲ 162% vs 2024 (€ 33) Favourable step	▲ 162%
Land & buildings	€ 311,586 Land & buildings 2022: € 311,586 First fiscal year in the series	€ 303,348 Land & buildings 2023: € 303,348 ▼ 3% vs 2022 (€ 311,586) Unchanged	€ 296,671 Land & buildings 2024: € 296,671 ▼ 2% vs 2023 (€ 303,348) Unchanged	€ 289,994 Land & buildings 2025: € 289,994 ▼ 2% vs 2024 (€ 296,671) Unchanged	▼ 2%
Retained profit	€ -84,202 Retained profit 2022: € -84,202 First fiscal year in the series	€ -76,982 Retained profit 2023: € -76,982 ▲ € 7,220 vs 2022 (€ -84,202) Favourable step	€ -68,322 Retained profit 2024: € -68,322 ▲ € 8,660 vs 2023 (€ -76,982) Favourable step	€ -72,414 Retained profit 2025: € -72,414 ▼ € 4,091 vs 2024 (€ -68,322) Unfavourable step	▼ € 4,091
Bank debt	€ 100,000 Bank debt 2022: € 100,000 First fiscal year in the series	€ 90,000 Bank debt 2023: € 90,000 ▼ 10% vs 2022 (€ 100,000) Favourable step	€ 90,000 Bank debt 2024: € 90,000 Unchanged (€ 90,000) Unchanged	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 90,000) Favourable step	▼ 100%
Balance sheet total	€ 317,421 Balance sheet total 2022: € 317,421 First fiscal year in the series	€ 304,011 Balance sheet total 2023: € 304,011 ▼ 4% vs 2022 (€ 317,421) Unchanged	€ 299,190 Balance sheet total 2024: € 299,190 ▼ 2% vs 2023 (€ 304,011) Unchanged	€ 290,081 Balance sheet total 2025: € 290,081 ▼ 3% vs 2024 (€ 299,190) Unchanged	▼ 3%

Key figures of DIFARMEX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DIFARMEX?

What happened at DIFARMEX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 30, 2026 New annual accounts for financial year 2025: loss of € 4,091 (▼ € 12,751 vs 2024). Source: NBB ↗
Apr 20, 1999 New establishment in Alken. KBO
Aug 5, 1994 Start of the company according to the CBE. KBO

In short

From € 5,975 profit in 2022 to € 4,091 loss in 2025.

Best year ever: 2024, with € 8,660 profit.

Original PDFs at the National Bank ↗

Management

Stephan Tans Maria Adams

GAMMA PROJECTS

DIFARMEX

Behind DIFARMEX are Stephan Tans and Maria Adams. Stephan Tans is also behind GAMMA PROJECTS.

Directors

According to the 2025 annual accounts

Stephan Tans

Managing director

Also active at: GAMMA PROJECTS

Maria Adams

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Koosterstraat 51

3570 Alken

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0453.209.833
VAT number: BE 0453.209.833
Registered office: Koosterstraat 51, 3570 Alken
Names & denominations: DIFARMEX
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 5 August 1994
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗